Initial testing of topotecan by the pediatric preclinical testing program.
about
Patient-derived tumour xenografts as models for oncology drug developmentSchedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma CellsOptimization of liposomal topotecan for use in treating neuroblastoma.Personalising pancreas cancer treatment: When tissue is the issue.Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directionsTesting of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upRapid screening of novel agents for combination therapy in sarcomasBiology and Treatment of Rhabdoid Tumor.Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.Childhood cancer and developmental biology a crucial partnership.
P2860
Q24604068-B963EC0C-D98A-4864-A6C9-C8DD8540B2B7Q28553176-F97B9FF1-855F-4ADE-A2D8-88AB48EE3961Q33775276-E0FDFE96-D71B-4FB5-82EC-15DDEE276F29Q33801384-CFE1CA3D-A0E5-49DA-B01F-48293ABB6E39Q34561518-91768417-DAD7-4B1E-8B42-9059D8ACDB07Q34660299-E9568DDD-6776-42FF-A512-B510A7638C71Q34787772-FF481E6D-14D6-485C-99C1-D9EAF2E937A9Q35161137-41F3AA09-3142-402D-96B7-D8CFD0E82D4FQ36205257-2B5D5A23-6667-494E-9749-ACA914D8BBF1Q36888962-D72832B0-BF09-4962-97DB-E2D3B05A0A49Q36970948-F1A52B5F-5129-4CD3-AB9D-DE5139B5F074Q37298877-1E9F952B-F0AE-46B3-B152-5BD6409A30E4Q38582867-CAA8D2CB-C0C1-4C0D-825B-9DE4114422FDQ42226188-6704E681-D1D4-4918-91B9-327CD08A448FQ42917104-98A4E337-1576-4F24-B31E-0B8A7A8D2B8F
P2860
Initial testing of topotecan by the pediatric preclinical testing program.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Initial testing of topotecan by the pediatric preclinical testing program.
@ast
Initial testing of topotecan by the pediatric preclinical testing program.
@en
Initial testing of topotecan by the pediatric preclinical testing program.
@nl
type
label
Initial testing of topotecan by the pediatric preclinical testing program.
@ast
Initial testing of topotecan by the pediatric preclinical testing program.
@en
Initial testing of topotecan by the pediatric preclinical testing program.
@nl
prefLabel
Initial testing of topotecan by the pediatric preclinical testing program.
@ast
Initial testing of topotecan by the pediatric preclinical testing program.
@en
Initial testing of topotecan by the pediatric preclinical testing program.
@nl
P2093
P2860
P50
P356
P1476
Initial testing of topotecan by the pediatric preclinical testing program
@en
P2093
Amy Watkins
Christopher L Morton
E Anders Kolb
Hernan Carol
John M Maris
Malcolm A Smith
Peter J Houghton
Stephen T Keir
P2860
P304
P356
10.1002/PBC.22352
P577
2010-05-01T00:00:00Z